Free tool
FAERS Monitor: Xofigo
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 203971 or its brand name (Xofigo, Radium Ra-223 Dichloride). Reports on generic versions are filed under their own applications.
Reports
5,055
Serious
4,481
89% of reports
Hospitalization
1,171
Death reported
1,036
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- prostatic specific antigen increased482
- death450
- hormone-refractory prostate cancer436
- metastases to bone327
- general physical health deterioration310
- anaemia285
- fatigue278
- haemoglobin decreased243
- nausea239
- pain234
- disease progression226
- prostate cancer221
- diarrhoea213
- malaise209
- asthenia197
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2013 | 77 |
| 2014 | 264 |
| 2015 | 365 |
| 2016 | 417 |
| 2017 | 697 |
| 2018 | 719 |
| 2019 | 581 |
| 2020 | 363 |
| 2021 | 496 |
| 2022 | 309 |
| 2023 | 230 |
| 2024 | 262 |
| 2025 | 168 |
| 2026 | 107 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,104 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hormone-refractory prostate cancerSignal | 436 | 2414.2 | 2152.6 | 664,257 |
| prostatic specific antigen increasedSignal | 482 | 150.8 | 138.3 | 69,121 |
| metastases to boneSignal | 327 | 84.6 | 76.1 | 26,402 |
| prostate cancerSignal | 221 | 11.5 | 10.1 | 2,102 |
| general physical health deteriorationSignal | 310 | 11.2 | 10.0 | 2,870 |
| haemoglobin decreasedSignal | 243 | 9.9 | 8.7 | 1,933 |
| disease progressionSignal | 226 | 8.0 | 7.0 | 1,374 |
| anaemiaSignal | 285 | 6.2 | 5.6 | 1,254 |
| astheniaSignal | 197 | 2.2 | 1.9 | 127 |
| deathSignal | 450 | 2.2 | 2.0 | 296 |
| malaise | 209 | 2.0 | 1.7 | 103 |
| pain | 234 | 1.6 | 1.4 | 51 |
| fatigue | 278 | 1.5 | 1.3 | 45 |
| diarrhoea | 213 | 1.4 | 1.2 | 22 |
| nausea | 239 | 1.3 | 1.1 | 13 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.